Table 2.
Immunohistochemical markers assessed and their significant association found in the reviewed studies.
| Studies | Immunohistochemical markers | Pretreatment | Treatment | Outcomes | Outcomes | Follow-up | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Response | Relapse | ||||||||||||
| Marker | Grade | Outcome | p value | Good | Poor | Yes | No | Marker | Outcome | p value | |||
| Kamoi [51] | Ki67 ssDNA ER PR |
NA | G1IA | NA | NA | MPA | 5 | 2 | — | — | NA | NA | NA |
|
| |||||||||||||
| Gunderson [46] | ER PR |
NA | AEH G1 |
NA | NA | MA | 30 | 16 | 7 | 23 | NA | NA | NA |
|
| |||||||||||||
| Yang [47] | ER PR Ki67 |
NA | AEH G1 |
NA | NA | MA MPA LNG-IUDs Norethisterone |
77 | 11 | 25 | 46 | ↑ Ki67 | R | 0.033 |
|
| |||||||||||||
| Reyes [48] | FOXO1 ER PR PRB |
NR | AEH G1 |
NA | NA | LNG-IUDs | 7 | 3 | — | — | ↑ ER ↑ PRB ↓ ER ↓ PR ↓ PRB |
PR PR GR GR GR |
< 0.05 < 0.05 < 0.01 < 0.01 < 0.05 |
|
| |||||||||||||
| Van Gent [52] | PTEN β-Catenin |
NA | G1IA | NA | NA | MA MPA MPA + LNG-IUDs |
6 | 5 | 5 | 1 | NR | NR | NR |
|
| |||||||||||||
| Wang [54] | Nrf2 AKR1C1 |
— | NR | — | — | NR | 11 | 10 | — | — | ↑ Nrf2 ↑AKR1C1 |
PR PR |
<0.0001 <0.0001 |
|
| |||||||||||||
| Li [49] | SPAG9 | NR | AEH G1IA |
NR | NR | MPA | 21 | 6 | — | — | ↓ SPAG9 | GR | 0.005 |
|
| |||||||||||||
| Fan [55] | Nrf2 Survivin |
— | NR | — | — | MPA + metformin | 18 | 17 | — | — | ↑ Nrf2 ↑ Survivin |
PR PR |
< 0.001 < 0.001 |
|
| |||||||||||||
| Zakhour [50] | MLH1 MSH2 MSH6 PMS2 |
MMR loss | AEH G1I A |
PR | 0.026 | Oral progestin +/- LNG-IUDs Oral + injectable progestin |
41 | 43 | — | — | — | — | — |
|
| |||||||||||||
| Chung [53] | P53 ER PR MLH1 MSH2 MSH6 PMS2 |
↓ MMR ↑ PR |
G1 G2 |
PR GR |
0.018 0.011 |
MPA MA MPA+ LNG-IUDs |
43 | 14 | 19 | 24 | NA | NA | 0,069 |
|
| |||||||||||||
| Westin [56] | Ki67 DDK3 PR EIG121 IGF-1/2 IGFBP1 RALDH2 SRFP1/4 Survivin FZD8/10 TCF7 Wnt5a |
↑ Ki67 | AEH | PR | 0.023 | LNG-IUDs | 37 | 10 | 4 | 33 | NR | NR | NR |
| ↓ DDK3 | G1 | PR | 0.030 | ||||||||||